Articles related to Endocrinology, Diabetes, Metabolism

An editorial in Obesity highlights emerging evidence that GLP-1 receptor agonists may provide benefits beyond weight loss and glycemic control, while emphasizing unresolved questions regarding muscle preservation, nutritional status, and potential effects on substance use disorders.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

A primary care physician describes combining nutrition counseling, individualized monitoring, and pharmacotherapy in obesity care. The interview offers a practice philosophy rather than comparative evidence supporting one treatment strategy.

Experts highlighted ongoing barriers and knowledge gaps affecting reproductive care for transgender and gender-diverse patients while outlining strategies to support pregnancy, postpartum care, and fertility discussions in affirming clinical environments.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.

Discontinuing statins in adults 75 years and older without prior cardiovascular disease did not increase mortality or major cardiovascular events over three years in a randomized trial. LDL cholesterol rose substantially after discontinuation, and longer-term effects remain uncertain.